OMass Therapeutics Raises €275 Million Series C for Small-Molecule Pipeline Oxford spin-out OMass Therapeutics has closed an oversubscribed €275 million (£230 million) Series C round to advance its small-molecule therapies, which target highly validated target ecosystems. The round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings. Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences also participated. Key takeaway: A €275 million oversubscribed round led by three new institutional backers signals that specialist life sciences capital remains available at scale for late-stage European biotech with differentiated discovery platforms. Source: EU-Startups Biotech #Funding #VC 🔗 https://www.eu-startups.com/2026/10/oxford-spin-out-omass-therapeutics-lands-e275-million-to-bring-novel-small-molecule-therapies-closer-to-patients/